Gordon C. Brandt
Chief Tech/Sci/R&D Officer at Profil Institute for Clinical Research, Inc.
Profile
Gordon C.
Brandt is a Senior Director of Clinical Development at Profil Institute for Clinical Research, Inc. He was previously the President of MDRNA, Inc. from 2002 to 2008, and Vice President of Clinical & Regulatory Affairs at Sonus Pharmaceuticals, Inc. He also served as the Chief Medical Officer at PhaseRx, Inc. from 2016 to 2017.
Brandt received his undergraduate degree from Yale University and his doctorate from The University of California, San Francisco.
Gordon C. Brandt active positions
| Companies | Position | Start |
|---|---|---|
Profil Institute for Clinical Research, Inc.
 Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Gordon C. Brandt
| Companies | Position | End |
|---|---|---|
| PHASERX, INC. | Chief Tech/Sci/R&D Officer | 2017-09-30 |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | President | 2008-09-29 |
Sonus Pharmaceuticals, Inc.
 Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Corporate Officer/Principal | - |
Training of Gordon C. Brandt
| Yale University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PHASERX, INC. | Health Technology |
| Private companies | 3 |
|---|---|
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | Commercial Services |
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Gordon C. Brandt